
Nexstim’s Quality System and NBS 6 Receive MDR Certification in the EU
Press release, Helsinki, 17May2023 at 2 PM (EEST)
Nexstim’s QualitySystem and NBS 6 Receive MDR Certification in the EU
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received certifications for its quality management system and NBS 6 product under MDR (Regulation (EU) 2017/745) in the European Union.
The EU quality management system certificate allows for Nexstim to start marketing and selling the NBS 6 system for the treatment of major depression and chronic neuropathic pain within the European Union. Nexstim announced on April 17, 2023, that it had launched NBS 6 in the United States for the treatment of Major Depressive Disorder (MDD).
The NBS 6 enables Nexstim’s unique E-field navigated TMS technology to be used more easily than ever before. Part of this new product generation is an easy-to-use, software-guided application and a modular product design that allows for system capabilities to expand over time and be highly customized based on a customer’s research or treatment interests.
Mikko Karvinen, CEO of Nexstim, comments:
“The MDR conformity certification is an important step in the process of launching theNBS 6 and achieving one of our keystrategic objectives for 2023. I am proud of the hard work our team has put into making the new software generation available in both the United States and the European Union in such a tight schedule. The EU quality management system certification will benefit us in the long term also by making any future product certification processes more efficient.
The NBS 6 received a great response as we attended and unveiled the product at the Clinical TMS Society Annual Meeting in Colorado Springs, United States earlier this month. We are expecting nothing less from the European market and are excited to continue the promotion work.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
RESULT OF RIKSBANK CERTIFICATE SALE28.11.2023 10:15:00 CET | Press release
AuctionAuction resultsAuction date2023-11-28Start date2023-11-29Maturity date2023-12-06Interest rate4.00 %Offered volume, SEK bn1 017.0Total bid amount, SEK bn923.6Accepted volume, SEK bn923.6Number of bids19Percentage allotted, %100.00
Ekstraordinære indfrielser (CK93)28.11.2023 10:00:00 CET | pressemeddelelse
KommuneKredit offentliggør hermed oplysninger om ekstraordinære indfrielser (CK93) pr. 24. november 2023. For yderligere informationer om dataformat og –indhold henvises til Nasdaqs hjemmeside. Med venlig hilsen KommuneKredit Vedhæftet fil Fortindf-24112023
International Petroleum Corporation Announces Appointment of New Director28.11.2023 10:00:00 CET | Press release
International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) is pleased to announce the appointment of Deborah Starkman to the Corporation's Board of Directors. The appointment is effective November 27, 2023 and increases the Board to seven directors. As previously announced, William Lundin will also be appointed to the Board as of January 1, 2024, increasing the Board to eight directors. Ms. Starkman is currently the Chief Financial Officer of Dream Unlimited Corp. (Dream), a TSX-listed real estate developer and asset management business in Canada and the United States. Ms. Starkman is responsible for overseeing the financial management of Dream. She currently oversees the shared services platform including Information and Technology, People and Culture, Office Services, Legal, Treasury and development accounting. Ms. Starkman was previously the Chief Financial Officer and Corporate Secretary of GMP Capital Inc. (GMP), a Canadian independent financial ser
Correction: CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES28.11.2023 09:44:11 CET | Press release
Bid date, 2023-11-28Auction date2023-11-28Settlement date2023-11-29Maturity Date2023-12-06Nominal amount1 017 billion SEKInterest rate4.00 %Bid times09.30-10.00 (CET/CEST) on the Bid dateBids are made to phone number08-696 69 70Confirmation of bids to e-mailrbcert@riksbank.seThe lowest accepted bid volume1 million SEKThe highest accepted bid volume1 017 billion SEKAllocation Time10.15 (CET/CEST) on the Bid dateProjected minimum liquidity surplus during the term1 017 billion SEKExpected excess liquidity at full allotment0 billion SEK Stockholm, 2023-11-28
CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES28.11.2023 09:30:00 CET | Press release
Bid date, 2023-11-28Auction date2023-11-28Settlement date2023-11-29Maturity Date2023-12-06Nominal amount1 117 billion SEKInterest rate4.00 %Bid times09.30-10.00 (CET/CEST) on the Bid dateBids are made to phone number08-696 69 70Confirmation of bids to e-mailrbcert@riksbank.seThe lowest accepted bid volume1 million SEKThe highest accepted bid volume1 117 billion SEKAllocation Time10.15 (CET/CEST) on the Bid dateProjected minimum liquidity surplus during the term1 117 billion SEKExpected excess liquidity at full allotment0 billion SEK Stockholm, 2023-11-28